Axsome Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

02.01.25	Biotech Stocks Facing FDA Decision In January 2025 (RTTNews)
04.09.24	Axsome Says FDA Acknowledges Resubmission Of NDA For AXS-07 For Migraine (RTTNews)
05.08.24	Axsome Therapeutics, Inc. Q2 Loss Increases, Misses Estimates (RTTNews)
05.06.24	Axsome Resolves Patent Litigation With Unichem - Quick Facts (RTTNews)
25.03.24	Axsome Therapeutics' Phase 3 SYMPHONY Study In Narcolepsy Meets Primary Goal (RTTNews)
19.03.24	Axsome Therapeutics Gains After Initiation Of Paradigm Phase 3 Trial Of Solriamfetol (RTTNews)
26.11.23	AXSM FINAL DEADLINE NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM (PR Newswire)
20.11.23	ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important December 7 Deadline in Securities Class Action - AXSM (PR Newswire)
28.06.23	Axsome Therapeutics Falls After Pricing 3 Mln Share Offering (RTTNews)
28.06.23	Pre-market Movers: ASTS, AREB, RNXT, COYA, BANL… (RTTNews)
08.05.23	Axsome Therapeutics Adds 7% As Q1 Results Better Than Consensus (RTTNews)
14.03.23	SHAREHOLDER ALERT: Axsome Therapeutics, Inc. (AXSM) Officers and Directors Face Shareholder Investigation for Alleged Securities Law Violations (PR Newswire)
22.02.23	Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe (GlobeNewswire)
03.10.22	Axsome Says Sunosi Met Primary Endpoint In SHARP Study (RTTNews)
19.08.22	Axsome Announces FDA Approval Of Auvelity For Treatment Of Major Depressive Disorder (RTTNews)
09.07.22	AXSM FINAL DEADLINE ALERT: ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM (PR Newswire)
01.07.22	ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM (PR Newswire)
23.06.22	AXSM LOSS ALERT: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM (PR Newswire)
14.06.22	AXSM SHAREHOLDER ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Cla... (PR Newswire)
08.06.22	AXSM SHAREHOLDER ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM (PR Newswire)
31.05.22	ROSEN, A GLOBALLY RECOGNIZED FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM (PR Newswire)
31.05.22	Axsome Therapeutics Announces Publication of Pivotal GEMINI Phase 3 Trial of AXS-05 in Major Depressive Disorder in The Journal of Clinical Psychiatry (PR Newswire)
25.05.22	Pre-market Movers: VRCA, CMRA, WEN, SPRC, NEGG… (RTTNews)
24.05.22	AXSM INVESTOR NOTICE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM (PR Newswire)
18.05.22	Axsome Therapeutics Announces Publication of Pivotal ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder in The American Journal of Psychiatry (PR Newswire)
17.05.22	SHAREHOLDER ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM (PR Newswire)
16.05.22	Axsome Therapeutics Supports the National Alliance on Mental Illness (NAMI) to Recognize Mental Health Awareness Month (PR Newswire)
09.05.22	Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea (PR Newswire)
03.05.22	TCMD Expects 13-15% Revenue Growth In 2022, AXSM On Watch, QURE Awaits Huntington's Trial Data (RTTNews)
02.05.22	Axsome Therapeutics Gets FDA CRL For AXS-07 NDA For Acute Treatment Of Migraine (RTTNews)
02.05.22	Axsome Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update (PR Newswire)
02.05.22	Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine (PR Newswire)
25.04.22	Axsome Therapeutics to Report First Quarter 2022 Financial Results on May 2, 2022 (PR Newswire)
19.04.22	Pre-market Movers: AXSM, SST, SAVA, ENSV, SMCI… (RTTNews)
28.03.22	Axsome To Buy Sunosi From Jazz (RTTNews)
28.03.22	Biotech Stocks Facing FDA Decision In April 2022 (RTTNews)
30.09.21	SHAREHOLDER ALERT: ROSEN, LEADING INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses Over $100K to Inquire About Class Action Investigation - AXSM (PR Newswire)
14.09.21	Axsome Therapeutics Says FDA Accepts AXS-07 NDA For Acute Treatment Of Migraine - Quick Facts (RTTNews)
29.07.21	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM (PR Newswire)
27.07.21	Biotech Stocks Facing FDA Decision In August 2021 (RTTNews)
18.07.21	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM (PR Newswire)
15.07.21	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axsome Therapeutics, Inc. - AXSM (PR Newswire)
31.12.20	Axsome Therapeutics Begins Phase 3 Trial Of AXS-05 In Alzheimer's Disease Agitation (RTTNews)
31.12.20	Axsome Reports Positive Results From Phase 3 Trial Of AXS-07 In Acute Treatment Of Migraine (RTTNews)
28.12.20	Biotech Stock Picks That Delivered Triple-digit Gains - Is There More Room To Run? (RTTNews)
24.09.20	Axsome Therapeutics: AXS-07 Shows Strong Efficacy In MOMENTUM Trial - Quick Facts (RTTNews)
26.06.20	Stock Alert: Axsome Therapeutics Climbs 9% As Its AXS-05 Gets Breakthrough Therapy Designation (RTTNews)
27.04.20	Stock Alert: Axsome Therapeutics Up 25% As Alzheimer's Drug Achieves Main Goal (RTTNews)
27.04.20	Axsome Therapeutics (AXSM) Advances To Cross $100-Mark (RTTNews)
31.03.20	AMRN Loses Legal Fight, AKRO Awaits Big Day, JNJ's Covid-19 Vaccine Study In Sep (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Geberit	510.00	3.09 %	K V
UBS Group	29.96	1.97 %	K V
Zurich Insur Gr	537.60	1.55 %	K V
Logitech Intl	80.34	1.47 %	K V
Swiss Life Hldg	717.00	1.36 %	K V
Kuehne+Nagel Int	200.90	0.45 %	K V
Swisscom	509.00	0.30 %	K V
Alcon	75.84	0.18 %	K V
Nestle	73.66	-0.67 %	K V
CieFinRichemont	139.05	-0.82 %	K V

Nachrichten zu Axsome Therapeutics Inc

Aktien Top/Flop

Meistgelesene Nachrichten